Elpiscience today announced that it will present the latest progress of its innovative molecules and powerful antibody generation platforms at the Biotech Showcase™ conference during J.P.Morgan
Elpiscience today announced that the China Center of Drug Evaluation (CDE) has cleared Elpiscience’s Investigational New Drug Application (IND) for ES014 to initiate a Phase 1 clinical study for
Elpiscience presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting
Elpiscience announced it will have five poster presentations at the SITC 2022 Annual Meeting.
ES014 is a first in class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways.
ES104 in combination with paclitaxel showed a high ORR including responses in all four BTC subtypes and good overall tolerability consistent with prior studies.